Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2

被引：76

作者：

Granados-Riveron, Javier T. ^{[1
]}

Aquino-Jarquin, Guillermo ^{[2
]}

机构：

[1] Hosp Infantil Mexico Dr Federico Gomez, Lab Invest Patogenesis Mol, Mexico City, DF, Mexico

[2] Hosp Infantil Mexico Dr Federico Gomez, Lab Invest Genom Genet & Bioinformat, Mexico City, DF, Mexico

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2021年 / 142卷

关键词：

SARS-CoV-2; Spike protein; MRNA; Nucleoside-modified; LNP; vaccines; DENDRITIC CELLS; LIPID NANOPARTICLES; PROTEIN EXPRESSION; IMMUNE-RESPONSES; DELIVERY; IMMUNOGENICITY; SPIKE; PSEUDOURIDINE; RECOGNITION; STABILITY;

D O I：

10.1016/j.biopha.2021.111953

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Currently, there are over 230 different COVID-19 vaccines under development around the world. At least three decades of scientific development in RNA biology, immunology, structural biology, genetic engineering, chemical modification, and nanoparticle technologies allowed the accelerated development of fully synthetic messenger RNA (mRNA)-based vaccines within less than a year since the first report of a SARS-CoV-2 infection. mRNA-based vaccines have been shown to elicit broadly protective immune responses, with the added advantage of being amenable to rapid and flexible manufacturing processes. This review recapitulates current advances in engineering the first two SARS-CoV-2-spike-encoding nucleoside-modified mRNA vaccines, highlighting the strategies followed to potentiate their effectiveness and safety, thus facilitating an agile response to the current COVID-19 pandemic.

引用

页数：11

共 124 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].

A Feldman, Robert ;

Fuhr, Rainard ;

Smolenov, Igor ;

Ribeiro, Amilcar ;

Panther, Lori ;

Watson, Mike ;

Senn, Joseph J. ;

Smith, Mike ;

Almarsson, Orn ;

Pujar, Hari S. ;

Laska, Michael E. ;

Thompson, James ;

Zaks, Tal ;

Ciaramella, Giuseppe .

VACCINE, 2019, 37 (25) :3326-3334

[2] COVID-19 and mRNA Vaccines-First Large Test for a New Approach [J].

Abbasi, Jennifer .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (12) :1125-1127

[3] Post-transcriptional pseudouridylation in mRNA as well as in some major types of noncoding RNAs [J].

Adachi, Hironori ;

De Zoysa, Meemanage D. ;

Yu, Yi-Tao .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2019, 1862 (03) :230-239

[4]

Alameh MG, 2022, CURR TOP MICROBIOL, V437, P111, DOI 10.1007/82_2020_202

[5] Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines [J].

Alfagih, Iman M. ;

Aldosari, Basmah ;

AlQuadeib, Bushra ;

Almurshedi, Alanood ;

Alfagih, Mariyam M. .

PHARMACEUTICS, 2021, 13 (01) :1-27

[6] Liposomal drug delivery systems: From concept to clinical applications [J].

Allen, Theresa M. ;

Cullis, Pieter R. .

ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48

[7] Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L [J].

Anderson, Bart R. ;

Muramatsu, Hiromi ;

Jha, Babal K. ;

Silverman, Robert H. ;

Weissman, Drew ;

Kariko, Katalin .

NUCLEIC ACIDS RESEARCH, 2011, 39 (21) :9329-9338

[8] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[9] N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice [J].

Andries, Oliwia ;

Mc Cafferty, Sean ;

De Smedt, Stefaan C. ;

Weiss, Ron ;

Sanders, Niek N. ;

Kitada, Tasuku .

JOURNAL OF CONTROLLED RELEASE, 2015, 217 :337-344

[10] Nanomedicine and the COVID-19 vaccines [J].

不详 .

NATURE NANOTECHNOLOGY, 2020, 15 (12) :963-963

← 1 2 3 4 5 6 7 8 9 10 →